Compare therapies beyond the scale.
Weight loss is only one outcome. RecompSignal compares evidence maturity, body composition, lean-mass evidence and regulatory status so very different therapies are not flattened into one number.
Start with the question you actually care about.
A therapy can have exceptional total-weight results while still having limited direct evidence about fat mass, lean mass or physical function. That is why RecompSignal keeps those domains separate.
| Therapy | Evidence maturity | Weight evidence strength | Fat/composition strength | Lean-mass strength | Status |
|---|---|---|---|---|---|
| Tirzepatide | M5 | 5/5 | 3/5 | 3/5 | Approved |
| Semaglutide | M5 | 5/5 | 2/5 | 2/5 | Approved |
| Retatrutide | M4 | 3/5 | 0/5 | 0/5 | Investigational |
| Bimagrumab | M3 | 3/5 | 4/5 | 4/5 | Investigational |
| Orforglipron | M5 | 5/5 | 0/5 | 0/5 | Approved |
Want the full evidence landscape?
Get the free 2026 Body-Recomposition Evidence Map with evidence maturity, body-composition signals and pipeline status in one reference.
Get the free Evidence MapContinue exploring
Broader coverage, study-specific comparisons
Orforglipron (Foundayo) is included in the approved-therapy evidence coverage. Its approval does not establish superior muscle preservation. Compare the 17 Signal Cards using population, formulation, study dose, comparator, duration and outcome method.
Compare the evidence—not just the percentages.
Mechanism, population, dose, duration, comparator and measurement method all change what a headline number means.
Open the detailed comparison